MedinCell
June 16, 2025
Company Presentation
Platform for Therapeutics
Medincell is a commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve effectiveness and accessibility, and to reduce the environmental footprint of drugs. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options.
Company HQ City:
Jacou
Company HQ State:
Occitanie Region
Company HQ Country:
France
Year Founded:
2003
Lead Product in Development:
UZEDY, an FDA approved 1 and 2-month subcutaneous reformulation of Risperidone for the treatment of Schizophrenia.
CEO
Christophe Douat
Year Founded
2003
Development Phase of Lead Product
Multiple Products in Market
Number of Unlicensed Products Looking for Licensing
1
Exchange
EPA
Ticker
MEDCL
When you expect your next catalyst update?
The 2 next catalyst update is mdc-TJK’s Ph3 readout and mdc-CWM’s regulatory meeting with the FDA. The next inflection point will be mdc-TJK’s NDA submission to FDA by our partner Teva Pharmaceuticals.
What is your next catalyst (value inflection) update?
January-June 2025, mdc-TJK’s Ph3 readout.
January-March 2025, mdc-CWM’s regulatory meeting with FDA
Website
https://www.medincell.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}